Jagdish Agrawal, a promoter of Ishita Drugs & Industries Ltd , has acquired additional equity shares in the pharmaceutical company through open market transactions. The acquisition was formally disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations governing substantial acquisition of shares.

Transaction Details

The share acquisition transaction involved specific parameters that demonstrate the promoter's continued investment in the company:

Shareholding Pattern Changes

The acquisition resulted in a marginal increase in Agrawal's ownership stake in the company. The following table illustrates the changes in his shareholding pattern:

The transaction represents a minimal increase in the promoter's stake, with the percentage holding rising by just 0.01 percentage points.

Company Capital Structure

Ishita Drugs & Industries Ltd maintains a stable capital structure following this transaction. The company's equity share capital remained unchanged at ₹2.99 crores, consisting of 2,990,300 equity shares with a face value of ₹10.00 each. The total diluted share capital also remains at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Agrawal, identified as a promoter of the company, fulfilled the mandatory reporting requirements by submitting the necessary documentation to BSE Limited within the prescribed timeframe. The company's shares are listed on BSE Limited under scrip code 524400.

Ishita Drugs & Industries Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2025, revealing a mixed performance amidst ongoing facility upgrades.

Financial Performance

The company reported revenue from operations of Rs. 806.81 lakhs for the quarter, contributing to a half-yearly revenue of Rs. 1499.73 lakhs. However, the net profit for the quarter saw a decline, coming in at Rs. 14.33 lakhs compared to Rs. 30.23 lakhs in the previous quarter.

The basic earnings per share (EPS) from continuing operations stood at Rs. 0.48 for the quarter.

Manufacturing Facility Upgrade

Ishita Drugs & Industries is currently undertaking a significant manufacturing facility upgradation project to comply with the Revised Schedule M regulations. The company's Board of Directors discussed the progress of this project during their meeting. Key points include:

1. Appointment of a civil contractor and commencement of construction.
2. Progress affected by higher-than-normal rainfall and an extended monsoon period.
3. Expenditure of nearly Rs. 50 lakhs incurred towards civil construction of the project.

Balance Sheet Highlights

As of September 30, 2025, the company's financial position shows:

Cash Flow and Liquidity

The cash flow statement reveals:

• Net cash generated from operating activities: Rs. 412.24 lakhs
• Net cash used in investing activities: Rs. 245.67 lakhs
• Net cash used in financing activities: Rs. 177.27 lakhs

This resulted in a net decrease of Rs. 10.70 lakhs in cash and cash equivalents for the half-year period.

The company maintains a strong liquidity position with cash and cash equivalents of Rs. 46.14 lakhs and bank balances of Rs. 426.54 lakhs as of September 30, 2025.

Ishita Drugs & Industries Limited continues to navigate through challenging market conditions while investing in its future growth through facility upgrades. The impact of these investments on the company's financial performance and market position remains to be seen in the coming quarters.